(Hong Kong, May 15, 2020) A leading domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets - Peijia Medical Limited (“Peijia Medical” or the “Company”, together with its subsidiaries, the “Group”, stock code: 9996), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”) today, with a board lot of 1,000 Shares.

The share price closed at HK$25.80 with an intra-day high of HK$27.15 per share, up approximatly 67.97% compared with the offer price. A total of approximately 93.14 million shares were traded, with an aggregate turnover of approximately HK$2.44 billion.

Dr. Yi Zhang, Executive Director, Chairman of the Board, Chief Executive Officer and Chief Technology Officer of Peijia Medical Limited, said, “Getting listed on the Hong Kong Stock Exchange successfully is an important milestone in the Company’s development. We are honored to receive enthusiastic support from all our investors. Standing at a new starting point, we will actively expand our business scale and further strengthen our research and development capabilities. Meanwhile, we plan to expedite the commercialization of our product candidates, expand the product portfolio, and continue to synergize the business and boost operational efficiency. It lays a solid foundation for the long-term development of the Company, with a view to creating fruitful value for our shareholders.”